XML 55 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Related Party Transactions - Collaboration and License Agreements (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 20, 2023
Dec. 31, 2023
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Related Party Transaction [Line Items]          
Common stock, shares issued     79,418,438   78,397,380
Offering costs     $ 12 $ 635  
Shares issued to related party     79,418,438   78,397,380
Service revenue - related party     $ 1,926 697 $ 697
Asset purchase agreement funding included in contract price of license agreement   $ 5,800      
Gain on sale of nonfinancial assets       29,018  
Janssen Pharmaceuticals Inc | Asset Purchase Agreement          
Related Party Transaction [Line Items]          
Service revenue - related party     1,900    
Deferred revenue recognized as service revenue during the period     741 700  
Initial agreement term 4 years        
Written days-notice to terminate agreement 90 days        
Milestone funding     60,000    
Non-refundable upfront cash funding   65,000      
Milestone funding for extension of RPGR product clinical trials     50,000 50,000  
Milestone funding for development of drug substances   10,000      
Milestone funding for development of drug products   5,000      
Milestone funding for sale of drug products in the US   175,000      
Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy   75,000      
Milestone funding for transfer of manufacturing technology   25,000      
Milestone funding upon regulatory approval   10,000      
Deferred revenue - related party included in contract price of license agreement   30,600      
Variable consideration for services included in contract price of license agreement   1,800      
Contract price of license agreement   92,300      
Offsetting credit for transition services   5,100      
Performance obligation for process performance qualification services   2,900      
Performance obligation for commercial supply of RPGR product   6,900      
Performance obligation for manufacturing technology transfer   28,700      
Performance obligation for sale of nonfinancial assets   53,800      
Milestone funding allocated to process performance qualification services     $ 10,000 1,600  
Milestone funding allocated to commercial supply of RPGR product       3,800  
Milestone funding allocated to manufacturing technology transfer       15,600  
Milestone funding allocated to sale of nonfinancial assets       $ 29,000  
Janssen Pharmaceuticals Inc | Asset Purchase Agreement | Maximum          
Related Party Transaction [Line Items]          
Contingent Funding Available   $ 350,000